The Role of Tau Oligomers in the Onset of Alzheimer's Disease Neuropathology

被引:97
作者
del Carmen Cardenas-Aguayo, Maria [1 ]
Gomez-Virgilio, Laura [1 ]
DeRosa, Steven [2 ]
Antonio Meraz-Rios, Marco [1 ]
机构
[1] CINVESTAV, IPN, Mol Biomed Dept, Mexico City 07360, DF, Mexico
[2] Nathan S Kline Inst Psychiat Res, Ctr Dementia Res, Orangeburg, NY 10962 USA
关键词
Tau oligomers; aggregation; neurodegeneration; Alzheimer's disease; protein spreading; synaptic impairment; new drug targets; proteasome; autophagy; PAIRED-HELICAL-FILAMENT; DEPENDENT AXONAL-TRANSPORT; SOLUBLE-PROTEIN OLIGOMERS; BRAIN-DERIVED TAU; MOUSE MODEL; HYPERPHOSPHORYLATED-TAU; NEUROFIBRILLARY TANGLES; PASSIVE-IMMUNIZATION; PHOSPHORYLATED-TAU; AMYLOID-BETA;
D O I
10.1021/cn500148z
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Most neurodegenerative diseases are characterized by the presence of protein aggregates. Alzheimer's disease (AD) is the most common cause of dementia in people over age 60. One of the histopathological hallmarks of AD is the presence of tau protein aggregates. Historically, it has been thought that paired helical filaments (PHFs) were the toxic form of tau that assembled to form neurofibrillary tangles (NFTs), but recently there has been evidence that tau oligomers, which form before PHFs and NFTs, could be the structures mediating neurodegeneration even before the fibrillary tau is deposited. Here, we discuss the recent advances in tau oligomer research, their implications on AD and other tauopathies, the mechanisms of tau turnover by the principal protein clearance systems (the proteasome and autophagy), and the potential use of tau oligomers as drug targets for the development of new therapeutic approaches.
引用
收藏
页码:1178 / 1191
页数:14
相关论文
共 146 条
[1]   Inhibition of Tau Filament Formation by Conformational Modulation [J].
Akoury, Elias ;
Gajda, Michal ;
Pickhard, Marcus ;
Biernat, Jacek ;
Soraya, Pornsuwan ;
Griesinger, Christian ;
Mandelkow, Eckhard ;
Zweckstetter, Markus .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2013, 135 (07) :2853-2862
[2]   NMNAT suppresses Tau-induced neurodegeneration by promoting clearance of hyperphosphorylated Tau oligomers in a Drosophila model of tauopathy [J].
Ali, Yousuf O. ;
Ruan, Kai ;
Zhai, R. Grace .
HUMAN MOLECULAR GENETICS, 2012, 21 (02) :237-250
[3]   ROLE OF ABNORMALLY PHOSPHORYLATED TAN IN THE BREAKDOWN OF MICROTUBULES IN ALZHEIMER-DISEASE [J].
ALONSO, AD ;
ZAIDI, T ;
GRUNDKEIQBAL, I ;
IQBAL, K .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (12) :5562-5566
[4]   Promotion of hyperphosphorylation by frontotemporal dementia tau mutations [J].
Alonso, AD ;
Mederlyova, A ;
Novak, M ;
Grundke-Iqbal, I ;
Iqbal, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (33) :34873-34881
[5]   Polymerization of hyperphosphorylated tau into filaments eliminates its inhibitory activity [J].
Alonso, Alejandra Del C. ;
Li, Bin ;
Grundke-Iqbal, Inge ;
Iqbal, Khalid .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (23) :8864-8869
[6]   Heat Shock Proteins as Suppressors of Accumulation of Toxic Prefibrillar Intermediates and Misfolded Proteins in Neurodegenerative Diseases [J].
Arawaka, Shigeki ;
Machiya, Youhei ;
Kato, Takeo .
CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2010, 11 (02) :158-166
[7]   Tau dephosphorylation at tau-1 site correlates with its association to cell membrane [J].
Arrasate, M ;
Pérez, M ;
Avila, J .
NEUROCHEMICAL RESEARCH, 2000, 25 (01) :43-50
[8]   Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements [J].
Asuni, Ayodeji A. ;
Boutajangout, Allal ;
Quartermain, David ;
Sigurdsson, Einar M. .
JOURNAL OF NEUROSCIENCE, 2007, 27 (34) :9115-9129
[9]  
AUER IA, 1995, ACTA NEUROPATHOL, V90, P547
[10]   Role of tau protein in both physiological and pathological conditions [J].
Avila, J ;
Lucas, JJ ;
Pérez, M ;
Hernández, F .
PHYSIOLOGICAL REVIEWS, 2004, 84 (02) :361-384